PL2393360T3 - Związki pirydazynonowe - Google Patents
Związki pirydazynonoweInfo
- Publication number
- PL2393360T3 PL2393360T3 PL10738857T PL10738857T PL2393360T3 PL 2393360 T3 PL2393360 T3 PL 2393360T3 PL 10738857 T PL10738857 T PL 10738857T PL 10738857 T PL10738857 T PL 10738857T PL 2393360 T3 PL2393360 T3 PL 2393360T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridazinone compounds
- pyridazinone
- compounds
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20220709P | 2009-02-05 | 2009-02-05 | |
| US21392709P | 2009-07-30 | 2009-07-30 | |
| PCT/US2010/000307 WO2010090737A1 (en) | 2009-02-05 | 2010-02-04 | Pyridazinone compounds |
| EP10738857.1A EP2393360B1 (en) | 2009-02-05 | 2010-02-04 | Pyridazinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2393360T3 true PL2393360T3 (pl) | 2016-04-29 |
Family
ID=42398214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10738857T PL2393360T3 (pl) | 2009-02-05 | 2010-02-04 | Związki pirydazynonowe |
Country Status (37)
| Country | Link |
|---|---|
| US (7) | US8354411B2 (pl) |
| EP (2) | EP3006031A1 (pl) |
| JP (1) | JP5659166B2 (pl) |
| KR (1) | KR101730665B1 (pl) |
| CN (1) | CN102365020B (pl) |
| AR (1) | AR075238A1 (pl) |
| AU (1) | AU2010211050B2 (pl) |
| BR (1) | BRPI1008498B8 (pl) |
| CA (1) | CA2751565C (pl) |
| CO (1) | CO6410258A2 (pl) |
| CR (1) | CR20110440A (pl) |
| DK (1) | DK2393360T3 (pl) |
| DO (1) | DOP2011000254A (pl) |
| EA (1) | EA020690B1 (pl) |
| EC (1) | ECSP11011305A (pl) |
| ES (1) | ES2561181T3 (pl) |
| GE (1) | GEP20146004B (pl) |
| HR (1) | HRP20160065T1 (pl) |
| HU (1) | HUE027478T2 (pl) |
| IL (1) | IL214137A (pl) |
| JO (1) | JO3114B1 (pl) |
| MA (1) | MA33072B1 (pl) |
| ME (1) | ME02337B (pl) |
| MX (1) | MX2011008305A (pl) |
| MY (1) | MY170610A (pl) |
| NZ (1) | NZ594851A (pl) |
| PE (1) | PE20110991A1 (pl) |
| PL (1) | PL2393360T3 (pl) |
| RS (1) | RS54504B1 (pl) |
| SG (1) | SG173175A1 (pl) |
| SI (1) | SI2393360T1 (pl) |
| SM (1) | SMT201600008B (pl) |
| TN (1) | TN2011000362A1 (pl) |
| TW (1) | TWI457333B (pl) |
| UY (1) | UY32417A (pl) |
| WO (1) | WO2010090737A1 (pl) |
| ZA (1) | ZA201106074B (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009054791A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5 |
| CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
| PL2393360T3 (pl) | 2009-02-05 | 2016-04-29 | Takeda Pharmaceuticals Co | Związki pirydazynonowe |
| EA022705B1 (ru) | 2010-06-24 | 2016-02-29 | Такеда Фармасьютикал Компани Лимитед | Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ) |
| WO2012009194A1 (en) * | 2010-07-12 | 2012-01-19 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| EP2601192B1 (en) | 2010-08-04 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| JP5800813B2 (ja) | 2010-08-04 | 2015-10-28 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2012018058A1 (ja) | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| EP2604597B1 (en) * | 2010-08-10 | 2017-01-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a |
| JP2013234123A (ja) * | 2010-09-03 | 2013-11-21 | Taisho Pharmaceutical Co Ltd | ３−ピラゾリル−２−ピリドン誘導体 |
| CA2827724A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| EP2687529B1 (en) | 2011-03-16 | 2016-07-13 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| EP2748158B1 (en) | 2011-08-22 | 2018-01-24 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (pde10a) in mammals |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US9212147B2 (en) | 2011-11-15 | 2015-12-15 | Takeda Pharmaceutical Company Limited | Dihydroxy aromatic heterocyclic compound |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| PE20151334A1 (es) * | 2013-02-21 | 2015-10-14 | Takeda Pharmaceutical | Metodo de produccion de compuestos de piridazinona |
| EP2975037A4 (en) | 2013-03-15 | 2016-08-10 | Daiichi Sankyo Co Ltd | benzothiophene derivative |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| MX370085B (es) * | 2013-09-12 | 2019-11-29 | Janssen Biopharma Inc | Compuestos de piridazinona y usos de los mismos. |
| WO2015038655A1 (en) | 2013-09-12 | 2015-03-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| ES2544869B2 (es) * | 2014-03-04 | 2016-01-18 | Universidade De Vigo | Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa |
| WO2015141662A1 (ja) | 2014-03-18 | 2015-09-24 | 武田薬品工業株式会社 | 固体分散体 |
| JP6525437B2 (ja) | 2014-04-02 | 2019-06-05 | インターミューン， インコーポレイテッド | 抗線維性ピリジノン |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| CN107531717B (zh) | 2015-03-11 | 2021-07-27 | 詹森生物制药有限公司 | 氮杂-吡啶酮化合物及其用途 |
| WO2016191935A1 (en) * | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| JP2019503346A (ja) | 2015-12-22 | 2019-02-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ベンゾピペリジン誘導体、その製造方法及びその医薬用途 |
| WO2019161179A1 (en) | 2018-02-15 | 2019-08-22 | Ovid Therapeutics Inc. | Methods of treating developmental syndromes with pde10a inhibitors |
| CN108498868B (zh) * | 2018-04-03 | 2020-09-15 | 北京大学口腔医学院 | 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法 |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| WO2019241787A1 (en) * | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use |
| EP3856185A1 (en) * | 2018-09-28 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| MX2019008440A (es) | 2019-07-15 | 2021-01-18 | Dva Farma Mexicana S A De C V | Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion. |
| GB202002926D0 (en) | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011693A1 (de) | 1978-10-03 | 1980-06-11 | Ciba-Geigy Ag | Neue N-(trifluormethansulfonylaminophenyl)-substituierte N-Heterocyclen, ihre Herstellung, sie enthaltende Mittel und ihre Verwendung zur Beeinflussung des Pflanzenwachstums |
| FR2648135B1 (fr) * | 1989-06-07 | 1991-09-27 | Pf Medicament | Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique |
| GB9506382D0 (en) * | 1995-03-29 | 1995-05-17 | Boots Co Plc | Pharmaceutical compositions |
| EP1130015A4 (en) | 1998-08-14 | 2006-02-08 | Nihon Nohyaku Co Ltd | PYRIDAZINONE DERIVATIVES |
| US20070060606A1 (en) * | 1999-10-07 | 2007-03-15 | Robertson Harold A | Compounds and methods for modulating phosphodiesterase 10A |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| KR20030032035A (ko) | 2000-09-15 | 2003-04-23 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| BRPI0511854A (pt) | 2004-06-07 | 2008-01-15 | Pfizer Prod Inc | inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica |
| EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
| JP4302762B2 (ja) | 2005-01-07 | 2009-07-29 | ファイザー・プロダクツ・インク | 複素環式芳香族キノリン化合物およびｐｄｅ１０阻害剤としてのその使用 |
| US7763617B2 (en) | 2005-03-07 | 2010-07-27 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient |
| WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS |
| WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
| TW201030001A (en) | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| CA2744489C (en) * | 2008-12-04 | 2015-06-23 | F.Hoffmann-La Roche Ag | Pyridazinone derivatives |
| PL2393360T3 (pl) * | 2009-02-05 | 2016-04-29 | Takeda Pharmaceuticals Co | Związki pirydazynonowe |
| US9187455B2 (en) * | 2009-02-23 | 2015-11-17 | Hoffmann-La Roche Inc. | Substituted pyridazines as PDE10A inhibitors |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| WO2012018058A1 (ja) * | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| EP2604597B1 (en) * | 2010-08-10 | 2017-01-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a |
-
2010
- 2010-02-04 PL PL10738857T patent/PL2393360T3/pl unknown
- 2010-02-04 KR KR1020117020556A patent/KR101730665B1/ko active Active
- 2010-02-04 US US13/148,172 patent/US8354411B2/en active Active
- 2010-02-04 MY MYPI2011003610A patent/MY170610A/en unknown
- 2010-02-04 EA EA201171004A patent/EA020690B1/ru not_active IP Right Cessation
- 2010-02-04 AR ARP100100304A patent/AR075238A1/es active IP Right Grant
- 2010-02-04 CA CA2751565A patent/CA2751565C/en active Active
- 2010-02-04 US US12/656,605 patent/US8916566B2/en active Active
- 2010-02-04 AU AU2010211050A patent/AU2010211050B2/en active Active
- 2010-02-04 SI SI201031103T patent/SI2393360T1/sl unknown
- 2010-02-04 JO JOP/2010/0038A patent/JO3114B1/ar active
- 2010-02-04 MA MA34133A patent/MA33072B1/fr unknown
- 2010-02-04 ME MEP-2016-194A patent/ME02337B/me unknown
- 2010-02-04 WO PCT/US2010/000307 patent/WO2010090737A1/en not_active Ceased
- 2010-02-04 HU HUE10738857A patent/HUE027478T2/en unknown
- 2010-02-04 UY UY0001032417A patent/UY32417A/es not_active Application Discontinuation
- 2010-02-04 DK DK10738857.1T patent/DK2393360T3/en active
- 2010-02-04 ES ES10738857.1T patent/ES2561181T3/es active Active
- 2010-02-04 TW TW099103286A patent/TWI457333B/zh active
- 2010-02-04 SG SG2011054491A patent/SG173175A1/en unknown
- 2010-02-04 EP EP15192646.6A patent/EP3006031A1/en not_active Withdrawn
- 2010-02-04 EP EP10738857.1A patent/EP2393360B1/en active Active
- 2010-02-04 JP JP2011549157A patent/JP5659166B2/ja active Active
- 2010-02-04 BR BRPI1008498A patent/BRPI1008498B8/pt active IP Right Grant
- 2010-02-04 PE PE2011001434A patent/PE20110991A1/es active IP Right Grant
- 2010-02-04 CN CN201080014965.6A patent/CN102365020B/zh active Active
- 2010-02-04 NZ NZ594851A patent/NZ594851A/xx unknown
- 2010-02-04 MX MX2011008305A patent/MX2011008305A/es active IP Right Grant
- 2010-02-04 GE GEAP201012363A patent/GEP20146004B/en unknown
- 2010-02-04 HR HRP20160065TT patent/HRP20160065T1/hr unknown
- 2010-02-04 RS RS20150859A patent/RS54504B1/sr unknown
-
2011
- 2011-07-18 IL IL214137A patent/IL214137A/en active IP Right Grant
- 2011-07-22 TN TN2011000362A patent/TN2011000362A1/fr unknown
- 2011-08-03 DO DO2011000254A patent/DOP2011000254A/es unknown
- 2011-08-17 CR CR20110440A patent/CR20110440A/es unknown
- 2011-08-18 ZA ZA2011/06074A patent/ZA201106074B/en unknown
- 2011-08-23 CO CO11106877A patent/CO6410258A2/es active IP Right Grant
- 2011-09-05 EC EC2011011305A patent/ECSP11011305A/es unknown
-
2012
- 2012-07-06 US US13/543,207 patent/US8778944B2/en active Active
- 2012-07-06 US US13/543,296 patent/US8513251B2/en active Active
- 2012-07-06 US US13/543,332 patent/US8435995B2/en active Active
-
2014
- 2014-10-17 US US14/517,313 patent/US9550756B2/en active Active
-
2016
- 2016-01-08 SM SM201600008T patent/SMT201600008B/it unknown
- 2016-12-13 US US15/377,149 patent/US20170114044A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201106074B (en) | Pyridazinone compounds | |
| GB0907425D0 (en) | Compounds | |
| EP2393493A4 (en) | LINKS | |
| GB0907515D0 (en) | Compounds | |
| ZA201105780B (en) | Pyridazinone derivatives | |
| GB0905641D0 (en) | Compounds | |
| GB0909671D0 (en) | Compounds | |
| GB0909672D0 (en) | Compounds | |
| AP2909A (en) | Pyrazinoisoquinoline Compounds | |
| EP2443115A4 (en) | COMPOUNDS | |
| ZA201105781B (en) | Pyridazinone derivatives | |
| GB0903948D0 (en) | Compounds | |
| GB0902391D0 (en) | Compounds | |
| GB0904746D0 (en) | Compounds | |
| GB0905054D0 (en) | Compounds | |
| GB0905057D0 (en) | Compounds | |
| GB0905060D0 (en) | Compounds | |
| GB0905062D0 (en) | Compounds | |
| GB0903492D0 (en) | Compounds | |
| GB0905932D0 (en) | Compounds | |
| GB0902796D0 (en) | Compounds | |
| GB0906433D0 (en) | Compounds | |
| GB0906853D0 (en) | Compounds | |
| GB0906854D0 (en) | Compounds | |
| GB0904729D0 (en) | Compounds |